E&G Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

E&G Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-291	Closed	-$207K	–	215
2024 Q4	$207K	Sell	291 -10	-3%	-$8.39K	0.06%	201
2024 Q3	$316K	Hold	301	–	–	0.09%	163
2024 Q2	$316K	Hold	301	–	–	0.09%	158
2024 Q1	$290K	Hold	301	–	–	0.09%	156
2023 Q4	$264K	Sell	301 -4	-1%	-$3.29K	0.09%	164
2023 Q3	$251K	Hold	305	–	–	0.09%	172
2023 Q2	$219K	Hold	305	–	–	0.08%	184
2023 Q1	$251K	Sell	305 -5	-2%	-$3.77K	0.09%	174
2022 Q4	$224K	Hold	310	–	–	0.08%	184
2022 Q3	$214K	Buy	+310	New	+$195K	0.08%	190
2022 Q2	–	Sell	-310	Closed	-$217K	–	216
2022 Q1	$217K	Buy	+310	New	+$196K	0.06%	205
2021 Q2	–	Hold	0	–	–	–	191

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

E&G Advisors's REGN Position: Q1 2025 in Review

E&G Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 291 shares — an estimated $207K sold.

E&G Advisors first reported a position in REGN in Q1 2022 and held it in 11 quarters. The position peaked at $316K in Q3 2024. 1,292 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

E&G Advisors reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
E&G Advisors sold 291 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $207K.
E&G Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2022 and held it in 11 quarters.
E&G Advisors's Regeneron Pharmaceuticals position peaked at $316K in Q3 2024.
1,292 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on E&G Advisors's 13F filing for Q1 2025, filed 23 Apr 2025.